Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

Both team's uniforms also one feature two of the more iconic, clean and classic helmets there are in college football, with Ohio State's classic silver sticker-adorned helmets clashing with Notre ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

Novavax (NVAX) ended the recent trading session at $8.55, demonstrating a +0.53% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.83% ...

These are jabs developed by Pfizer Biontech, Moderna and AstraZeneca. While the Novavax and the Sanofi GSK vaccines will not be part of the module, it will look at the circumstances surrounding ...

As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...